Drugs / GS-1720
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05585307 | Oct 2022 → Feb 2024 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-1720 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05585307 ↗ |
| Route | Oral | “Administered orally” NCT05585307 ↗ |